Yamashita Taku, Shinden Seiichi, Watabe Takahisa, Shiotani Akihiro
Department of Otolaryngology-Head and Neck Surgery, National Defense Medical Collage, 3-2 Namiki, Tokorozawa, Saitama 359-8513, Japan.
Anticancer Res. 2009 Feb;29(2):577-81.
This retrospective study evaluates the efficacy and safety of S-1 chemotherapy or S-1 followed by low-dose docetaxel chemotherapy for recurrent head and neck cancer.
S-1 was administered to 21 patients with recurrent head and neck cancer, in outpatient settings. Of these 21 patients, 8 were additionally administered a low dose of docetaxel fortnightly.
The survival rate of patients with squamous cell carcinoma of the head and neck was 59.1% for 12 months and 17.5% for 24 months, with a median survival time of 18 months. Time to progression of more than 12 months was shown by 4 patients (22.2%). Most adverse events were mild (up to grade 2).
S-1 therapy is considered a safe and effective treatment option. From the viewpoint of tumour dormancy, S-1 therapy is a useful vigorous anticancer treatment that can be provided while maintaining patients' quality of life in recurrent cases.
本回顾性研究评估了S-1化疗或S-1序贯低剂量多西他赛化疗用于复发性头颈癌的疗效和安全性。
21例复发性头颈癌患者在门诊接受S-1治疗。这21例患者中，8例额外每两周接受一次低剂量多西他赛治疗。
头颈鳞状细胞癌患者的12个月生存率为59.1%，24个月生存率为17.5%，中位生存时间为18个月。4例患者（22.2%）的疾病进展时间超过12个月。大多数不良事件为轻度（最高2级）。
S-1治疗被认为是一种安全有效的治疗选择。从肿瘤休眠的角度来看，S-1治疗是一种有用的积极抗癌治疗方法，在复发病例中可在维持患者生活质量的同时进行。
